Fibroblast growth factor receptor 2 (Fgfr2) plays an important role in eyelid and skin formation and patterning

Citation
Cl. Li et al., Fibroblast growth factor receptor 2 (Fgfr2) plays an important role in eyelid and skin formation and patterning, DEV DYNAM, 222(3), 2001, pp. 471-483
Citations number
56
Categorie Soggetti
Cell & Developmental Biology
Journal title
DEVELOPMENTAL DYNAMICS
ISSN journal
10588388 → ACNP
Volume
222
Issue
3
Year of publication
2001
Pages
471 - 483
Database
ISI
SICI code
1058-8388(200111)222:3<471:FGFR2(>2.0.ZU;2-6
Abstract
Initiating as protruding ridges above and below the optic vesicle, the eyel ids of mice grow across the eye and temporarily fuse in fetal life. Mutatio ns of a number of genes disrupt this developmental process and result in a birth defect, "open-eyelids at birth." Here we show that a critical event f or eyelid induction occurs at embryonic day 11.5 (E11.5) when the single ce ll-layered ectoderm in the presumptive eyelid territory increases prolifera tion and undergoes morphologic transition to form cube-shaped epithelial ce lls. Using embryos lacking the Fgfr2 Ig domain III (Fgfr2(Delta III/Delta I II)) generated by tetraploid rescue and chimeric embryo formation approache s, we demonstrate that this event is controlled by Fgfr2 signals as the Fgf r2(Delta III/Delta III) mutation blocks these changes and results in embryo s without eyelids. Fgfr2 and its ligands are differentially expressed in th e ectoderm and underlying mesenchyme and function in a reciprocal interacti ng loop that specifies eyelid development. We also demonstrate that similar defects account for failure of skin formation at early stages. Interesting ly, Fgfr2-independent skin formation occurs at E14.5 mutant embryos, result ing in much thinner, yet well-differentiated epidermis. Notably, mutant ski n remains thin with decreased hair density after transplantation to wild-ty pe recipients. These data demonstrate an essential role of Fgfr2 in eyelid and skin formation and patterning. Published 2001 Wiley-Liss, Inc.